Asset profile
GIC-102
Cell therapy
Evidence outlook · results not reported
NCT05880043 · Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory...
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
NCT05880043: This is an early-stage, single-group study with no randomization, no blinding, and no comparison group, aimed at establishing a safe and tolerable dose before any efficacy claim can be made. With no control arm and no results posted, this cannot support more than a weak rating.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 60 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| GIC-102: this drug | Phase 1/2 | Cell therapy | Allogeneic natural killer (NK) cell therapy (non-CAR) | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| Ixazomib | Approved | Small molecule | Proteasome | ||
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Melphalan Flufenamide | Approved | Small molecule | DNA (alkylation), delivered via aminopeptidase-mediated intracellular activation | ||
| Melphalan Hydrochloride (Evomela) | Approved | Small molecule | DNA (guanine N7 position) |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.